BRISBANE, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that it will release its financial results for the third quarter of 2014 after the close of trading on November 10, 2014. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (855) 420-0616 for domestic callers or (678) 304-6848 for international callers. Please reference Conference ID 21235007. To listen to a live webcast, please visit the investor relations section of CareDx's website at: www.caredxinc.com.
A replay of the call will be available beginning November 10, 2014 at 4:30pm PT/7:30pm ET through midnight on November 11, 2014. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 21235007. The webcast will also be available on CareDx's website for one year following the completion of the call.
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. For more information, please visit: www.CareDxInc.com.
CONTACT: Westwicke Partners, LLC Leigh J. Salvo, Principal Tel: 415-513-1281 firstname.lastname@example.org